Editas Medicine, Inc.
EDIT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650664
In the last 90 days, Editas Medicine, Inc. insiders filed 0 open-market purchases and 5 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $386.3M in total; no superinvestor holds it.
Superinvestors holding EDIT, Q2 2026
No superinvestor reported holding EDIT in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of EDIT each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2023
0 superinvestors holding at quarter end
- Sold out
- ARK Invest
Q4 2022
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−100.0%)
Q3 2022
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−42.6%)
Q2 2022
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−68.2%)
Q1 2022
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−81.1%)
Q4 2021
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−33.0%)
Q3 2021
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−12.3%)
Q2 2021
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−18.0%)
- Sold out
- Maverick Capital